Research programme: recombinant human factor VIII - GTC Biotherapeutics/ProGenetics

Drug Profile

Research programme: recombinant human factor VIII - GTC Biotherapeutics/ProGenetics

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ProGenetics
  • Developer ProGenetics; rEVO Biologics
  • Class Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Haemophilia A

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Haemophilia-A in USA (Parenteral)
  • 07 Dec 2010 GTC Biotherapeutics has been acquired by LFB Biotechnologies
  • 06 Dec 2007 Recombinant human factor VIII, factor IX and fibrinogen licensed to GTC Biotherapeutics in North America, Europe and Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top